"Phthalazines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Bicyclic heterocyclic compounds containing a BENZENE ring fused to PYRIDAZINE.
Descriptor ID |
D010793
|
MeSH Number(s) |
D03.383.710.605
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Phthalazines".
Below are MeSH descriptors whose meaning is more specific than "Phthalazines".
This graph shows the total number of publications written about "Phthalazines" by people in this website by year, and whether "Phthalazines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1997 | 0 | 1 | 1 |
2003 | 1 | 0 | 1 |
2004 | 0 | 1 | 1 |
2005 | 1 | 1 | 2 |
2006 | 1 | 2 | 3 |
2007 | 1 | 0 | 1 |
2010 | 2 | 1 | 3 |
2011 | 1 | 2 | 3 |
2012 | 2 | 2 | 4 |
2013 | 1 | 0 | 1 |
2014 | 3 | 2 | 5 |
2015 | 2 | 1 | 3 |
2016 | 1 | 3 | 4 |
2017 | 10 | 2 | 12 |
2018 | 4 | 2 | 6 |
2019 | 4 | 9 | 13 |
2020 | 4 | 2 | 6 |
2021 | 4 | 7 | 11 |
2022 | 1 | 7 | 8 |
2023 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Phthalazines" by people in Profiles.
-
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma. Br J Cancer. 2024 02; 130(3):476-482.
-
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial. J Clin Oncol. 2024 Jan 20; 42(3):283-299.
-
Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance. Clin Cancer Res. 2022 10 14; 28(20):4536-4550.
-
Tumor Immune Microenvironment Changes by Multiplex Immunofluorescence Staining in a Pilot Study of Neoadjuvant Talazoparib for Early-Stage Breast Cancer Patients with a Hereditary BRCA Mutation. Clin Cancer Res. 2022 09 01; 28(17):3669-3676.
-
Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer. JAMA Oncol. 2022 09 01; 8(9):1317-1322.
-
Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer. Clin Lung Cancer. 2022 07; 23(5):e325-e329.
-
Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer. Clin Cancer Res. 2022 04 14; 28(8):1493-1499.
-
Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer. Clin Cancer Res. 2022 04 01; 28(7):1383-1390.
-
Evaluation of pharmacokinetics and safety of talazoparib in patients with advanced cancer and varying degrees of hepatic impairment. Br J Clin Pharmacol. 2022 07; 88(7):3392-3403.
-
Enhanced cytotoxicity of bisantrene when combined with venetoclax, panobinostat, decitabine and olaparib in acute myeloid leukemia cells. Leuk Lymphoma. 2022 07; 63(7):1634-1644.